Asta Medica, Aktiengesellschaft

Harald Borbe

Klaus Wessel

Helmut Hettche

Heinz Ulrich

Lester Packer

Amira Klip

Hans Bisswanger

J&uuml;rgen Engel

Michael Lobisch

Jean Schoenen

Manfred Peukert

Use of R-(&plus;)-&agr;-lipoic acid, R-(&minus;)-dihydrolipoic acid and metabolites in the form of the free acid or as salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae

The invention relates to the use of racemic &agr;-lipoic acid or its enantiomers or pharmaceutically acceptable salts, amides, esters or thioesters thereof, in reduced or oxidized form, as active ingredient in the prevention or the acute or chronic treatment of migraine.

Treatment of migraine by administration of &agr;-lipoic acid or derivatives thereof

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance. These drugs mentioned can also be used advantageously in combination with other antidiabetic drugs, particularly with insulin, and/or other additives or stabilizers or adjuvants, such as vitamin E, vitamin C, NADH, NADPH and ubiquinone. The invention furthermore relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, as well as their salts, esters and amides for the preparation of drugs for the treatment of diseases with limited function of or a lowered content of the glucose transporters.

Use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid and

The invention relates to the use of R-(+)-.alpha.-lipoic acid, R-(-)-dihydrolipoic acid or their metabolites, salts, esters and amides for the synthesis of drugs for the treatment of diabetes mellitus of types I and II, compensated and decompensated insulin resistance and sequelae or late complications of diabetes mellitus, such as cataracts, polyneuropathy, nephropathy, as well as sequelae or late complications of insulin resistance.

Use of R-(+)-.alpha.-lipoic acid, R-(-)dihydrolipoic acid and

Growing community of inventors

Mainz, Germany

Harald Borbe